Kancera AB Cash And Equivalents vs. Net Income
| KAN Stock | SEK 1.02 0.08 7.27% |
For Kancera AB profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kancera AB to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kancera AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kancera AB's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kancera AB over time as well as its relative position and ranking within its peers.
Kancera |
Kancera AB Net Income vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kancera AB's current stock value. Our valuation model uses many indicators to compare Kancera AB value to that of its competitors to determine the firm's financial worth. Kancera AB is currently regarded as number one stock in cash and equivalents category among its peers. It also is currently regarded as number one stock in net income category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kancera AB's earnings, one of the primary drivers of an investment's value.Kancera Net Income vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Kancera AB |
| = | 106.52 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Kancera AB |
| = | (45.69 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Kancera Net Income Comparison
Kancera AB is currently under evaluation in net income category among its peers.
Kancera AB Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kancera AB, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kancera AB will eventually generate negative long term returns. The profitability progress is the general direction of Kancera AB's change in net profit over the period of time. It can combine multiple indicators of Kancera AB, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Kancera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kancera AB. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kancera AB position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kancera AB's important profitability drivers and their relationship over time.
Use Kancera AB in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kancera AB position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kancera AB will appreciate offsetting losses from the drop in the long position's value.Kancera AB Pair Trading
Kancera AB Pair Trading Analysis
The ability to find closely correlated positions to Kancera AB could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kancera AB when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kancera AB - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kancera AB to buy it.
The correlation of Kancera AB is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kancera AB moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kancera AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kancera AB can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kancera AB position
In addition to having Kancera AB in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Giant Impact Thematic Idea Now
Giant Impact
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.